Literature DB >> 28162900

Discovery and structure activity relationship of the first potent cryptosporidium FIKK kinase inhibitor.

Khan T Osman1, Juntao Ye2, Zhihao Shi3, Christina Toker2, Diogo Lovato4, Rajiv S Jumani5, William Zuercher6, Christopher D Huston5, Aled M Edwards4, Mark Lautens2, Vijayaratnam Santhakumar7, Raymond Hui4.   

Abstract

FIKKs are parasite-specific protein kinases with distinctive sequence motifs and their biological roles have not been completely elucidated. Here, we report the first potent Cryptosporidium FIKK (CpFIKK) inhibitor. We identified 4b as a potent (IC50=0.2nM) inhibitor of CpFIKK catalytic activity. In addition, we identified both CpCDPK1 selective as well as dually acting CpFIKK-CDPK1 inhibitors from the same structural class of compounds. We evaluated these CpFIKK inhibitors for inhibition of parasite growth in vitro. The observed effects on parasite growth did not correlate with CpFIKK inhibition, suggesting that CpFIKK may not be involved in parasite growth.
Copyright © 2017 Elsevier Ltd. All rights reserved.

Keywords:  Cryptosporidium; FIKK Kinase inhibitor; Kinase inhibitor

Mesh:

Substances:

Year:  2017        PMID: 28162900     DOI: 10.1016/j.bmc.2017.01.036

Source DB:  PubMed          Journal:  Bioorg Med Chem        ISSN: 0968-0896            Impact factor:   3.641


  4 in total

Review 1.  Synthetic Strategies, Reactivity and Applications of 1,5-Naphthyridines.

Authors:  Maria Fuertes; Carme Masdeu; Endika Martin-Encinas; Asier Selas; Gloria Rubiales; Francisco Palacios; Concepcion Alonso
Journal:  Molecules       Date:  2020-07-16       Impact factor: 4.411

2.  FIKK Kinase, a Ser/Thr Kinase Important to Malaria Parasites, Is Inhibited by Tyrosine Kinase Inhibitors.

Authors:  Benjamin C Lin; Darcy R Harris; Lucy M D Kirkman; Astrid M Perez; Yiwen Qian; Janse T Schermerhorn; Min Y Hong; Dennis S Winston; Lingyin Xu; Gabriel S Brandt
Journal:  ACS Omega       Date:  2017-10-11

3.  Identification of a potent benzoxaborole drug candidate for treating cryptosporidiosis.

Authors:  Christopher S Lunde; Erin E Stebbins; Rajiv S Jumani; Md Mahmudul Hasan; Peter Miller; John Barlow; Yvonne R Freund; Pamela Berry; Rianna Stefanakis; Jiri Gut; Philip J Rosenthal; Melissa S Love; Case W McNamara; Eric Easom; Jacob J Plattner; Robert T Jacobs; Christopher D Huston
Journal:  Nat Commun       Date:  2019-06-27       Impact factor: 14.919

4.  Plasmodial Kinase Inhibitors: License to Cure?

Authors:  Diego González Cabrera; André Horatscheck; Colin R Wilson; Greg Basarab; Charles J Eyermann; Kelly Chibale
Journal:  J Med Chem       Date:  2018-06-04       Impact factor: 7.446

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.